nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxylamine—Tamoxifen—pancreatic cancer	0.584	1	CrCtD
Doxylamine—Toremifene—Tamoxifen—pancreatic cancer	0.0475	0.137	CrCrCtD
Doxylamine—Methadyl Acetate—Tamoxifen—pancreatic cancer	0.0316	0.0909	CrCrCtD
Doxylamine—Levomethadyl Acetate—Tamoxifen—pancreatic cancer	0.0316	0.0909	CrCrCtD
Doxylamine—Cyclobenzaprine—Tamoxifen—pancreatic cancer	0.0297	0.0855	CrCrCtD
Doxylamine—Dextropropoxyphene—Tamoxifen—pancreatic cancer	0.0259	0.0746	CrCrCtD
Doxylamine—Tripelennamine—Tamoxifen—pancreatic cancer	0.0247	0.0711	CrCrCtD
Doxylamine—Dimetacrine—Tamoxifen—pancreatic cancer	0.0231	0.0665	CrCrCtD
Doxylamine—Bromodiphenhydramine—Tamoxifen—pancreatic cancer	0.0231	0.0665	CrCrCtD
Doxylamine—Methadone—Tamoxifen—pancreatic cancer	0.0217	0.0624	CrCrCtD
Doxylamine—Clofedanol—Tamoxifen—pancreatic cancer	0.0187	0.054	CrCrCtD
Doxylamine—Orphenadrine—Tamoxifen—pancreatic cancer	0.0181	0.0522	CrCrCtD
Doxylamine—Benzphetamine—Tamoxifen—pancreatic cancer	0.0181	0.0522	CrCrCtD
Doxylamine—Promazine—Tamoxifen—pancreatic cancer	0.0173	0.0498	CrCrCtD
Doxylamine—Diphenhydramine—Tamoxifen—pancreatic cancer	0.0161	0.0464	CrCrCtD
Doxylamine—Pruritus—Erlotinib—pancreatic cancer	0.000111	0.00197	CcSEcCtD
Doxylamine—Discomfort—Fluorouracil—pancreatic cancer	0.00011	0.00196	CcSEcCtD
Doxylamine—Nervous system disorder—Irinotecan—pancreatic cancer	0.000109	0.00195	CcSEcCtD
Doxylamine—Thrombocytopenia—Irinotecan—pancreatic cancer	0.000109	0.00195	CcSEcCtD
Doxylamine—Anaphylactic shock—Gemcitabine—pancreatic cancer	0.000109	0.00194	CcSEcCtD
Doxylamine—Hepatitis—Docetaxel—pancreatic cancer	0.000108	0.00193	CcSEcCtD
Doxylamine—Diarrhoea—Tamoxifen—pancreatic cancer	0.000108	0.00193	CcSEcCtD
Doxylamine—Hyperhidrosis—Irinotecan—pancreatic cancer	0.000108	0.00192	CcSEcCtD
Doxylamine—Confusional state—Fluorouracil—pancreatic cancer	0.000108	0.00192	CcSEcCtD
Doxylamine—Urinary tract disorder—Docetaxel—pancreatic cancer	0.000107	0.00191	CcSEcCtD
Doxylamine—Diarrhoea—Erlotinib—pancreatic cancer	0.000107	0.00191	CcSEcCtD
Doxylamine—Anaphylactic shock—Fluorouracil—pancreatic cancer	0.000107	0.0019	CcSEcCtD
Doxylamine—Nervous system disorder—Gemcitabine—pancreatic cancer	0.000106	0.0019	CcSEcCtD
Doxylamine—Urethral disorder—Docetaxel—pancreatic cancer	0.000106	0.0019	CcSEcCtD
Doxylamine—Thrombocytopenia—Gemcitabine—pancreatic cancer	0.000106	0.0019	CcSEcCtD
Doxylamine—Anorexia—Irinotecan—pancreatic cancer	0.000106	0.00189	CcSEcCtD
Doxylamine—Diplopia—Epirubicin—pancreatic cancer	0.000106	0.00189	CcSEcCtD
Doxylamine—Hyperhidrosis—Gemcitabine—pancreatic cancer	0.000105	0.00187	CcSEcCtD
Doxylamine—Nervous system disorder—Fluorouracil—pancreatic cancer	0.000105	0.00187	CcSEcCtD
Doxylamine—Thrombocytopenia—Fluorouracil—pancreatic cancer	0.000105	0.00186	CcSEcCtD
Doxylamine—Dizziness—Tamoxifen—pancreatic cancer	0.000104	0.00186	CcSEcCtD
Doxylamine—Tachycardia—Fluorouracil—pancreatic cancer	0.000104	0.00186	CcSEcCtD
Doxylamine—Hypotension—Irinotecan—pancreatic cancer	0.000104	0.00186	CcSEcCtD
Doxylamine—Affect lability—Epirubicin—pancreatic cancer	0.000104	0.00186	CcSEcCtD
Doxylamine—Anorexia—Gemcitabine—pancreatic cancer	0.000103	0.00185	CcSEcCtD
Doxylamine—Dizziness—Erlotinib—pancreatic cancer	0.000103	0.00184	CcSEcCtD
Doxylamine—Erythema multiforme—Docetaxel—pancreatic cancer	0.000103	0.00183	CcSEcCtD
Doxylamine—Anorexia—Fluorouracil—pancreatic cancer	0.000102	0.00181	CcSEcCtD
Doxylamine—Hypotension—Gemcitabine—pancreatic cancer	0.000101	0.00181	CcSEcCtD
Doxylamine—Eye disorder—Docetaxel—pancreatic cancer	0.000101	0.00181	CcSEcCtD
Doxylamine—Insomnia—Irinotecan—pancreatic cancer	0.000101	0.0018	CcSEcCtD
Doxylamine—Cardiac disorder—Docetaxel—pancreatic cancer	0.000101	0.00179	CcSEcCtD
Doxylamine—Flushing—Docetaxel—pancreatic cancer	0.000101	0.00179	CcSEcCtD
Doxylamine—Vomiting—Tamoxifen—pancreatic cancer	0.0001	0.00179	CcSEcCtD
Doxylamine—Mood swings—Epirubicin—pancreatic cancer	0.0001	0.00179	CcSEcCtD
Doxylamine—Hypotension—Fluorouracil—pancreatic cancer	9.98e-05	0.00178	CcSEcCtD
Doxylamine—Hypersensitivity—Sunitinib—pancreatic cancer	9.97e-05	0.00178	CcSEcCtD
Doxylamine—Rash—Tamoxifen—pancreatic cancer	9.96e-05	0.00178	CcSEcCtD
Doxylamine—Dermatitis—Tamoxifen—pancreatic cancer	9.95e-05	0.00177	CcSEcCtD
Doxylamine—Vomiting—Erlotinib—pancreatic cancer	9.94e-05	0.00177	CcSEcCtD
Doxylamine—Dyspnoea—Irinotecan—pancreatic cancer	9.94e-05	0.00177	CcSEcCtD
Doxylamine—Somnolence—Irinotecan—pancreatic cancer	9.91e-05	0.00177	CcSEcCtD
Doxylamine—Rash—Erlotinib—pancreatic cancer	9.86e-05	0.00176	CcSEcCtD
Doxylamine—Dermatitis—Erlotinib—pancreatic cancer	9.85e-05	0.00176	CcSEcCtD
Doxylamine—Dehydration—Epirubicin—pancreatic cancer	9.83e-05	0.00175	CcSEcCtD
Doxylamine—Insomnia—Gemcitabine—pancreatic cancer	9.82e-05	0.00175	CcSEcCtD
Doxylamine—Immune system disorder—Docetaxel—pancreatic cancer	9.8e-05	0.00175	CcSEcCtD
Doxylamine—Diplopia—Doxorubicin—pancreatic cancer	9.78e-05	0.00174	CcSEcCtD
Doxylamine—Mediastinal disorder—Docetaxel—pancreatic cancer	9.77e-05	0.00174	CcSEcCtD
Doxylamine—Asthenia—Sunitinib—pancreatic cancer	9.71e-05	0.00173	CcSEcCtD
Doxylamine—Decreased appetite—Irinotecan—pancreatic cancer	9.69e-05	0.00173	CcSEcCtD
Doxylamine—Dyspnoea—Gemcitabine—pancreatic cancer	9.68e-05	0.00173	CcSEcCtD
Doxylamine—Orthostatic hypotension—Epirubicin—pancreatic cancer	9.66e-05	0.00172	CcSEcCtD
Doxylamine—Insomnia—Fluorouracil—pancreatic cancer	9.66e-05	0.00172	CcSEcCtD
Doxylamine—Somnolence—Gemcitabine—pancreatic cancer	9.65e-05	0.00172	CcSEcCtD
Doxylamine—Affect lability—Doxorubicin—pancreatic cancer	9.63e-05	0.00172	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Irinotecan—pancreatic cancer	9.62e-05	0.00172	CcSEcCtD
Doxylamine—Fatigue—Irinotecan—pancreatic cancer	9.61e-05	0.00171	CcSEcCtD
Doxylamine—Pruritus—Sunitinib—pancreatic cancer	9.57e-05	0.00171	CcSEcCtD
Doxylamine—Breast disorder—Epirubicin—pancreatic cancer	9.56e-05	0.0017	CcSEcCtD
Doxylamine—Constipation—Irinotecan—pancreatic cancer	9.53e-05	0.0017	CcSEcCtD
Doxylamine—Toxic epidermal necrolysis—Epirubicin—pancreatic cancer	9.52e-05	0.0017	CcSEcCtD
Doxylamine—Dyspnoea—Fluorouracil—pancreatic cancer	9.52e-05	0.0017	CcSEcCtD
Doxylamine—Somnolence—Fluorouracil—pancreatic cancer	9.49e-05	0.00169	CcSEcCtD
Doxylamine—Nasopharyngitis—Epirubicin—pancreatic cancer	9.46e-05	0.00169	CcSEcCtD
Doxylamine—Erythema—Docetaxel—pancreatic cancer	9.44e-05	0.00168	CcSEcCtD
Doxylamine—Decreased appetite—Gemcitabine—pancreatic cancer	9.44e-05	0.00168	CcSEcCtD
Doxylamine—Nausea—Tamoxifen—pancreatic cancer	9.38e-05	0.00167	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	9.37e-05	0.00167	CcSEcCtD
Doxylamine—Fatigue—Gemcitabine—pancreatic cancer	9.36e-05	0.00167	CcSEcCtD
Doxylamine—Constipation—Gemcitabine—pancreatic cancer	9.29e-05	0.00166	CcSEcCtD
Doxylamine—Nausea—Erlotinib—pancreatic cancer	9.28e-05	0.00166	CcSEcCtD
Doxylamine—Decreased appetite—Fluorouracil—pancreatic cancer	9.28e-05	0.00165	CcSEcCtD
Doxylamine—Mood swings—Doxorubicin—pancreatic cancer	9.27e-05	0.00165	CcSEcCtD
Doxylamine—Diarrhoea—Sunitinib—pancreatic cancer	9.26e-05	0.00165	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	9.22e-05	0.00164	CcSEcCtD
Doxylamine—Feeling abnormal—Irinotecan—pancreatic cancer	9.19e-05	0.00164	CcSEcCtD
Doxylamine—Dehydration—Doxorubicin—pancreatic cancer	9.1e-05	0.00162	CcSEcCtD
Doxylamine—Muscle spasms—Docetaxel—pancreatic cancer	9.08e-05	0.00162	CcSEcCtD
Doxylamine—Pancreatitis—Epirubicin—pancreatic cancer	8.96e-05	0.0016	CcSEcCtD
Doxylamine—Dizziness—Sunitinib—pancreatic cancer	8.95e-05	0.0016	CcSEcCtD
Doxylamine—Feeling abnormal—Gemcitabine—pancreatic cancer	8.95e-05	0.0016	CcSEcCtD
Doxylamine—Orthostatic hypotension—Doxorubicin—pancreatic cancer	8.94e-05	0.00159	CcSEcCtD
Doxylamine—Breast disorder—Doxorubicin—pancreatic cancer	8.84e-05	0.00158	CcSEcCtD
Doxylamine—Toxic epidermal necrolysis—Doxorubicin—pancreatic cancer	8.81e-05	0.00157	CcSEcCtD
Doxylamine—Feeling abnormal—Fluorouracil—pancreatic cancer	8.8e-05	0.00157	CcSEcCtD
Doxylamine—Nasopharyngitis—Doxorubicin—pancreatic cancer	8.75e-05	0.00156	CcSEcCtD
Doxylamine—Pancytopenia—Epirubicin—pancreatic cancer	8.68e-05	0.00155	CcSEcCtD
Doxylamine—Vomiting—Sunitinib—pancreatic cancer	8.6e-05	0.00153	CcSEcCtD
Doxylamine—Rash—Sunitinib—pancreatic cancer	8.53e-05	0.00152	CcSEcCtD
Doxylamine—Dermatitis—Sunitinib—pancreatic cancer	8.52e-05	0.00152	CcSEcCtD
Doxylamine—Urticaria—Fluorouracil—pancreatic cancer	8.48e-05	0.00151	CcSEcCtD
Doxylamine—Leukopenia—Docetaxel—pancreatic cancer	8.45e-05	0.00151	CcSEcCtD
Doxylamine—Palpitations—Docetaxel—pancreatic cancer	8.34e-05	0.00149	CcSEcCtD
Doxylamine—Pancreatitis—Doxorubicin—pancreatic cancer	8.29e-05	0.00148	CcSEcCtD
Doxylamine—Hypersensitivity—Irinotecan—pancreatic cancer	8.21e-05	0.00146	CcSEcCtD
Doxylamine—Convulsion—Docetaxel—pancreatic cancer	8.18e-05	0.00146	CcSEcCtD
Doxylamine—Drowsiness—Epirubicin—pancreatic cancer	8.15e-05	0.00145	CcSEcCtD
Doxylamine—Stevens-Johnson syndrome—Epirubicin—pancreatic cancer	8.08e-05	0.00144	CcSEcCtD
Doxylamine—Nausea—Sunitinib—pancreatic cancer	8.04e-05	0.00143	CcSEcCtD
Doxylamine—Pancytopenia—Doxorubicin—pancreatic cancer	8.03e-05	0.00143	CcSEcCtD
Doxylamine—Asthenia—Irinotecan—pancreatic cancer	8e-05	0.00143	CcSEcCtD
Doxylamine—Hypersensitivity—Fluorouracil—pancreatic cancer	7.87e-05	0.0014	CcSEcCtD
Doxylamine—Dry mouth—Docetaxel—pancreatic cancer	7.86e-05	0.0014	CcSEcCtD
Doxylamine—Sweating—Epirubicin—pancreatic cancer	7.81e-05	0.00139	CcSEcCtD
Doxylamine—Asthenia—Gemcitabine—pancreatic cancer	7.79e-05	0.00139	CcSEcCtD
Doxylamine—Confusional state—Docetaxel—pancreatic cancer	7.77e-05	0.00139	CcSEcCtD
Doxylamine—Anaphylactic shock—Docetaxel—pancreatic cancer	7.71e-05	0.00137	CcSEcCtD
Doxylamine—Pruritus—Gemcitabine—pancreatic cancer	7.68e-05	0.00137	CcSEcCtD
Doxylamine—Diarrhoea—Irinotecan—pancreatic cancer	7.63e-05	0.00136	CcSEcCtD
Doxylamine—Agranulocytosis—Epirubicin—pancreatic cancer	7.6e-05	0.00136	CcSEcCtD
Doxylamine—Nervous system disorder—Docetaxel—pancreatic cancer	7.56e-05	0.00135	CcSEcCtD
Doxylamine—Pruritus—Fluorouracil—pancreatic cancer	7.55e-05	0.00135	CcSEcCtD
Doxylamine—Thrombocytopenia—Docetaxel—pancreatic cancer	7.54e-05	0.00135	CcSEcCtD
Doxylamine—Drowsiness—Doxorubicin—pancreatic cancer	7.54e-05	0.00134	CcSEcCtD
Doxylamine—Tachycardia—Docetaxel—pancreatic cancer	7.52e-05	0.00134	CcSEcCtD
Doxylamine—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	7.48e-05	0.00133	CcSEcCtD
Doxylamine—Bradycardia—Epirubicin—pancreatic cancer	7.45e-05	0.00133	CcSEcCtD
Doxylamine—Diarrhoea—Gemcitabine—pancreatic cancer	7.43e-05	0.00132	CcSEcCtD
Doxylamine—Dizziness—Irinotecan—pancreatic cancer	7.37e-05	0.00131	CcSEcCtD
Doxylamine—Anorexia—Docetaxel—pancreatic cancer	7.34e-05	0.00131	CcSEcCtD
Doxylamine—Hepatitis—Epirubicin—pancreatic cancer	7.32e-05	0.0013	CcSEcCtD
Doxylamine—Diarrhoea—Fluorouracil—pancreatic cancer	7.3e-05	0.0013	CcSEcCtD
Doxylamine—Sweating—Doxorubicin—pancreatic cancer	7.23e-05	0.00129	CcSEcCtD
Doxylamine—Urinary tract disorder—Epirubicin—pancreatic cancer	7.22e-05	0.00129	CcSEcCtD
Doxylamine—Hypotension—Docetaxel—pancreatic cancer	7.2e-05	0.00128	CcSEcCtD
Doxylamine—Urethral disorder—Epirubicin—pancreatic cancer	7.17e-05	0.00128	CcSEcCtD
Doxylamine—Vomiting—Irinotecan—pancreatic cancer	7.09e-05	0.00126	CcSEcCtD
Doxylamine—Dizziness—Fluorouracil—pancreatic cancer	7.06e-05	0.00126	CcSEcCtD
Doxylamine—Agranulocytosis—Doxorubicin—pancreatic cancer	7.04e-05	0.00125	CcSEcCtD
Doxylamine—Rash—Irinotecan—pancreatic cancer	7.03e-05	0.00125	CcSEcCtD
Doxylamine—Dermatitis—Irinotecan—pancreatic cancer	7.02e-05	0.00125	CcSEcCtD
Doxylamine—Insomnia—Docetaxel—pancreatic cancer	6.97e-05	0.00124	CcSEcCtD
Doxylamine—Erythema multiforme—Epirubicin—pancreatic cancer	6.92e-05	0.00123	CcSEcCtD
Doxylamine—Vomiting—Gemcitabine—pancreatic cancer	6.9e-05	0.00123	CcSEcCtD
Doxylamine—Bradycardia—Doxorubicin—pancreatic cancer	6.89e-05	0.00123	CcSEcCtD
Doxylamine—Dyspnoea—Docetaxel—pancreatic cancer	6.87e-05	0.00122	CcSEcCtD
Doxylamine—Somnolence—Docetaxel—pancreatic cancer	6.85e-05	0.00122	CcSEcCtD
Doxylamine—Rash—Gemcitabine—pancreatic cancer	6.85e-05	0.00122	CcSEcCtD
Doxylamine—Dermatitis—Gemcitabine—pancreatic cancer	6.84e-05	0.00122	CcSEcCtD
Doxylamine—Eye disorder—Epirubicin—pancreatic cancer	6.84e-05	0.00122	CcSEcCtD
Doxylamine—Cardiac disorder—Epirubicin—pancreatic cancer	6.79e-05	0.00121	CcSEcCtD
Doxylamine—Flushing—Epirubicin—pancreatic cancer	6.79e-05	0.00121	CcSEcCtD
Doxylamine—Vomiting—Fluorouracil—pancreatic cancer	6.79e-05	0.00121	CcSEcCtD
Doxylamine—Hepatitis—Doxorubicin—pancreatic cancer	6.77e-05	0.00121	CcSEcCtD
Doxylamine—Rash—Fluorouracil—pancreatic cancer	6.73e-05	0.0012	CcSEcCtD
Doxylamine—Dermatitis—Fluorouracil—pancreatic cancer	6.72e-05	0.0012	CcSEcCtD
Doxylamine—Decreased appetite—Docetaxel—pancreatic cancer	6.7e-05	0.00119	CcSEcCtD
Doxylamine—Urinary tract disorder—Doxorubicin—pancreatic cancer	6.68e-05	0.00119	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Docetaxel—pancreatic cancer	6.65e-05	0.00119	CcSEcCtD
Doxylamine—Fatigue—Docetaxel—pancreatic cancer	6.64e-05	0.00118	CcSEcCtD
Doxylamine—Urethral disorder—Doxorubicin—pancreatic cancer	6.64e-05	0.00118	CcSEcCtD
Doxylamine—Nausea—Irinotecan—pancreatic cancer	6.62e-05	0.00118	CcSEcCtD
Doxylamine—Immune system disorder—Epirubicin—pancreatic cancer	6.61e-05	0.00118	CcSEcCtD
Doxylamine—Mediastinal disorder—Epirubicin—pancreatic cancer	6.59e-05	0.00118	CcSEcCtD
Doxylamine—Constipation—Docetaxel—pancreatic cancer	6.59e-05	0.00117	CcSEcCtD
Doxylamine—Nausea—Gemcitabine—pancreatic cancer	6.45e-05	0.00115	CcSEcCtD
Doxylamine—Erythema multiforme—Doxorubicin—pancreatic cancer	6.4e-05	0.00114	CcSEcCtD
Doxylamine—Erythema—Epirubicin—pancreatic cancer	6.37e-05	0.00114	CcSEcCtD
Doxylamine—Feeling abnormal—Docetaxel—pancreatic cancer	6.35e-05	0.00113	CcSEcCtD
Doxylamine—Nausea—Fluorouracil—pancreatic cancer	6.34e-05	0.00113	CcSEcCtD
Doxylamine—Eye disorder—Doxorubicin—pancreatic cancer	6.33e-05	0.00113	CcSEcCtD
Doxylamine—Cardiac disorder—Doxorubicin—pancreatic cancer	6.28e-05	0.00112	CcSEcCtD
Doxylamine—Flushing—Doxorubicin—pancreatic cancer	6.28e-05	0.00112	CcSEcCtD
Doxylamine—Muscle spasms—Epirubicin—pancreatic cancer	6.12e-05	0.00109	CcSEcCtD
Doxylamine—Immune system disorder—Doxorubicin—pancreatic cancer	6.11e-05	0.00109	CcSEcCtD
Doxylamine—Mediastinal disorder—Doxorubicin—pancreatic cancer	6.1e-05	0.00109	CcSEcCtD
Doxylamine—Ill-defined disorder—Epirubicin—pancreatic cancer	5.91e-05	0.00105	CcSEcCtD
Doxylamine—Erythema—Doxorubicin—pancreatic cancer	5.89e-05	0.00105	CcSEcCtD
Doxylamine—Agitation—Epirubicin—pancreatic cancer	5.85e-05	0.00104	CcSEcCtD
Doxylamine—Malaise—Epirubicin—pancreatic cancer	5.74e-05	0.00102	CcSEcCtD
Doxylamine—Vertigo—Epirubicin—pancreatic cancer	5.72e-05	0.00102	CcSEcCtD
Doxylamine—Leukopenia—Epirubicin—pancreatic cancer	5.7e-05	0.00102	CcSEcCtD
Doxylamine—Hypersensitivity—Docetaxel—pancreatic cancer	5.68e-05	0.00101	CcSEcCtD
Doxylamine—Muscle spasms—Doxorubicin—pancreatic cancer	5.66e-05	0.00101	CcSEcCtD
Doxylamine—Palpitations—Epirubicin—pancreatic cancer	5.63e-05	0.001	CcSEcCtD
Doxylamine—Asthenia—Docetaxel—pancreatic cancer	5.53e-05	0.000986	CcSEcCtD
Doxylamine—Convulsion—Epirubicin—pancreatic cancer	5.52e-05	0.000984	CcSEcCtD
Doxylamine—Ill-defined disorder—Doxorubicin—pancreatic cancer	5.47e-05	0.000975	CcSEcCtD
Doxylamine—Pruritus—Docetaxel—pancreatic cancer	5.45e-05	0.000972	CcSEcCtD
Doxylamine—Agitation—Doxorubicin—pancreatic cancer	5.41e-05	0.000965	CcSEcCtD
Doxylamine—Anxiety—Epirubicin—pancreatic cancer	5.4e-05	0.000963	CcSEcCtD
Doxylamine—Discomfort—Epirubicin—pancreatic cancer	5.36e-05	0.000955	CcSEcCtD
Doxylamine—Malaise—Doxorubicin—pancreatic cancer	5.31e-05	0.000947	CcSEcCtD
Doxylamine—Dry mouth—Epirubicin—pancreatic cancer	5.3e-05	0.000945	CcSEcCtD
Doxylamine—Vertigo—Doxorubicin—pancreatic cancer	5.29e-05	0.000944	CcSEcCtD
Doxylamine—Leukopenia—Doxorubicin—pancreatic cancer	5.27e-05	0.00094	CcSEcCtD
Doxylamine—Diarrhoea—Docetaxel—pancreatic cancer	5.27e-05	0.00094	CcSEcCtD
Doxylamine—Confusional state—Epirubicin—pancreatic cancer	5.24e-05	0.000934	CcSEcCtD
Doxylamine—Palpitations—Doxorubicin—pancreatic cancer	5.21e-05	0.000928	CcSEcCtD
Doxylamine—Anaphylactic shock—Epirubicin—pancreatic cancer	5.2e-05	0.000927	CcSEcCtD
Doxylamine—Convulsion—Doxorubicin—pancreatic cancer	5.11e-05	0.00091	CcSEcCtD
Doxylamine—Nervous system disorder—Epirubicin—pancreatic cancer	5.1e-05	0.000909	CcSEcCtD
Doxylamine—Dizziness—Docetaxel—pancreatic cancer	5.1e-05	0.000908	CcSEcCtD
Doxylamine—Thrombocytopenia—Epirubicin—pancreatic cancer	5.09e-05	0.000907	CcSEcCtD
Doxylamine—Tachycardia—Epirubicin—pancreatic cancer	5.07e-05	0.000904	CcSEcCtD
Doxylamine—Hyperhidrosis—Epirubicin—pancreatic cancer	5.02e-05	0.000896	CcSEcCtD
Doxylamine—Anxiety—Doxorubicin—pancreatic cancer	5e-05	0.000891	CcSEcCtD
Doxylamine—Discomfort—Doxorubicin—pancreatic cancer	4.96e-05	0.000884	CcSEcCtD
Doxylamine—Anorexia—Epirubicin—pancreatic cancer	4.95e-05	0.000883	CcSEcCtD
Doxylamine—Dry mouth—Doxorubicin—pancreatic cancer	4.91e-05	0.000875	CcSEcCtD
Doxylamine—Vomiting—Docetaxel—pancreatic cancer	4.9e-05	0.000873	CcSEcCtD
Doxylamine—Rash—Docetaxel—pancreatic cancer	4.86e-05	0.000866	CcSEcCtD
Doxylamine—Hypotension—Epirubicin—pancreatic cancer	4.86e-05	0.000866	CcSEcCtD
Doxylamine—Dermatitis—Docetaxel—pancreatic cancer	4.85e-05	0.000865	CcSEcCtD
Doxylamine—Confusional state—Doxorubicin—pancreatic cancer	4.85e-05	0.000864	CcSEcCtD
Doxylamine—Anaphylactic shock—Doxorubicin—pancreatic cancer	4.81e-05	0.000857	CcSEcCtD
Doxylamine—Nervous system disorder—Doxorubicin—pancreatic cancer	4.72e-05	0.000841	CcSEcCtD
Doxylamine—Thrombocytopenia—Doxorubicin—pancreatic cancer	4.71e-05	0.000839	CcSEcCtD
Doxylamine—Insomnia—Epirubicin—pancreatic cancer	4.7e-05	0.000838	CcSEcCtD
Doxylamine—Tachycardia—Doxorubicin—pancreatic cancer	4.69e-05	0.000837	CcSEcCtD
Doxylamine—Hyperhidrosis—Doxorubicin—pancreatic cancer	4.65e-05	0.000829	CcSEcCtD
Doxylamine—Dyspnoea—Epirubicin—pancreatic cancer	4.63e-05	0.000826	CcSEcCtD
Doxylamine—Somnolence—Epirubicin—pancreatic cancer	4.62e-05	0.000824	CcSEcCtD
Doxylamine—Anorexia—Doxorubicin—pancreatic cancer	4.58e-05	0.000817	CcSEcCtD
Doxylamine—Nausea—Docetaxel—pancreatic cancer	4.58e-05	0.000816	CcSEcCtD
Doxylamine—Decreased appetite—Epirubicin—pancreatic cancer	4.52e-05	0.000805	CcSEcCtD
Doxylamine—Hypotension—Doxorubicin—pancreatic cancer	4.49e-05	0.000801	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Epirubicin—pancreatic cancer	4.49e-05	0.0008	CcSEcCtD
Doxylamine—Fatigue—Epirubicin—pancreatic cancer	4.48e-05	0.000799	CcSEcCtD
Doxylamine—Constipation—Epirubicin—pancreatic cancer	4.44e-05	0.000792	CcSEcCtD
Doxylamine—Insomnia—Doxorubicin—pancreatic cancer	4.35e-05	0.000775	CcSEcCtD
Doxylamine—Dyspnoea—Doxorubicin—pancreatic cancer	4.29e-05	0.000764	CcSEcCtD
Doxylamine—Feeling abnormal—Epirubicin—pancreatic cancer	4.28e-05	0.000764	CcSEcCtD
Doxylamine—Somnolence—Doxorubicin—pancreatic cancer	4.28e-05	0.000762	CcSEcCtD
Doxylamine—Decreased appetite—Doxorubicin—pancreatic cancer	4.18e-05	0.000745	CcSEcCtD
Doxylamine—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	4.15e-05	0.00074	CcSEcCtD
Doxylamine—Fatigue—Doxorubicin—pancreatic cancer	4.15e-05	0.000739	CcSEcCtD
Doxylamine—Urticaria—Epirubicin—pancreatic cancer	4.13e-05	0.000736	CcSEcCtD
Doxylamine—Constipation—Doxorubicin—pancreatic cancer	4.11e-05	0.000733	CcSEcCtD
Doxylamine—Feeling abnormal—Doxorubicin—pancreatic cancer	3.96e-05	0.000707	CcSEcCtD
Doxylamine—Hypersensitivity—Epirubicin—pancreatic cancer	3.83e-05	0.000683	CcSEcCtD
Doxylamine—Urticaria—Doxorubicin—pancreatic cancer	3.82e-05	0.000681	CcSEcCtD
Doxylamine—Asthenia—Epirubicin—pancreatic cancer	3.73e-05	0.000665	CcSEcCtD
Doxylamine—Pruritus—Epirubicin—pancreatic cancer	3.68e-05	0.000656	CcSEcCtD
Doxylamine—Diarrhoea—Epirubicin—pancreatic cancer	3.56e-05	0.000634	CcSEcCtD
Doxylamine—Hypersensitivity—Doxorubicin—pancreatic cancer	3.54e-05	0.000632	CcSEcCtD
Doxylamine—Asthenia—Doxorubicin—pancreatic cancer	3.45e-05	0.000615	CcSEcCtD
Doxylamine—Dizziness—Epirubicin—pancreatic cancer	3.44e-05	0.000613	CcSEcCtD
Doxylamine—Pruritus—Doxorubicin—pancreatic cancer	3.4e-05	0.000607	CcSEcCtD
Doxylamine—Vomiting—Epirubicin—pancreatic cancer	3.3e-05	0.000589	CcSEcCtD
Doxylamine—Diarrhoea—Doxorubicin—pancreatic cancer	3.29e-05	0.000587	CcSEcCtD
Doxylamine—Rash—Epirubicin—pancreatic cancer	3.28e-05	0.000584	CcSEcCtD
Doxylamine—Dermatitis—Epirubicin—pancreatic cancer	3.27e-05	0.000584	CcSEcCtD
Doxylamine—Dizziness—Doxorubicin—pancreatic cancer	3.18e-05	0.000567	CcSEcCtD
Doxylamine—Nausea—Epirubicin—pancreatic cancer	3.09e-05	0.00055	CcSEcCtD
Doxylamine—Vomiting—Doxorubicin—pancreatic cancer	3.06e-05	0.000545	CcSEcCtD
Doxylamine—Rash—Doxorubicin—pancreatic cancer	3.03e-05	0.000541	CcSEcCtD
Doxylamine—Dermatitis—Doxorubicin—pancreatic cancer	3.03e-05	0.00054	CcSEcCtD
Doxylamine—Nausea—Doxorubicin—pancreatic cancer	2.86e-05	0.000509	CcSEcCtD
Doxylamine—HRH1—GPCR ligand binding—CNR1—pancreatic cancer	2.64e-05	0.00203	CbGpPWpGaD
Doxylamine—CHRM1—GPCR ligand binding—CNR1—pancreatic cancer	2.63e-05	0.00203	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—PPY—pancreatic cancer	2.62e-05	0.00202	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—PPY—pancreatic cancer	2.61e-05	0.00202	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—SSTR2—pancreatic cancer	2.57e-05	0.00199	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—SSTR2—pancreatic cancer	2.57e-05	0.00198	CbGpPWpGaD
Doxylamine—HRH1—GPCR ligand binding—GCG—pancreatic cancer	2.54e-05	0.00196	CbGpPWpGaD
Doxylamine—CHRM1—GPCR ligand binding—GCG—pancreatic cancer	2.54e-05	0.00196	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—CCKBR—pancreatic cancer	2.49e-05	0.00192	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—CCKBR—pancreatic cancer	2.48e-05	0.00191	CbGpPWpGaD
Doxylamine—HRH1—GPCR ligand binding—AGTR1—pancreatic cancer	2.43e-05	0.00187	CbGpPWpGaD
Doxylamine—CHRM1—GPCR ligand binding—AGTR1—pancreatic cancer	2.42e-05	0.00187	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—GAST—pancreatic cancer	2.35e-05	0.00182	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—GAST—pancreatic cancer	2.35e-05	0.00181	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—SCT—pancreatic cancer	2.23e-05	0.00172	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—SCT—pancreatic cancer	2.22e-05	0.00172	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—GAST—pancreatic cancer	2.14e-05	0.00165	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—GAST—pancreatic cancer	2.13e-05	0.00164	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—CCK—pancreatic cancer	2.13e-05	0.00164	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—CCK—pancreatic cancer	2.12e-05	0.00164	CbGpPWpGaD
Doxylamine—CHRM1—Regulation of Actin Cytoskeleton—NRAS—pancreatic cancer	2.12e-05	0.00163	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—CNR2—pancreatic cancer	2.07e-05	0.0016	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—GLP1R—pancreatic cancer	2.07e-05	0.0016	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—CNR2—pancreatic cancer	2.07e-05	0.0016	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—GLP1R—pancreatic cancer	2.07e-05	0.0016	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—CCKAR—pancreatic cancer	2.04e-05	0.00157	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—CCKAR—pancreatic cancer	2.03e-05	0.00157	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—SCT—pancreatic cancer	2.03e-05	0.00156	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—SCT—pancreatic cancer	2.02e-05	0.00156	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PRLHR—pancreatic cancer	1.94e-05	0.00149	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—CCK—pancreatic cancer	1.93e-05	0.00149	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PRLHR—pancreatic cancer	1.93e-05	0.00149	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—CCK—pancreatic cancer	1.93e-05	0.00149	CbGpPWpGaD
Doxylamine—CHRM1—Regulation of Actin Cytoskeleton—EGFR—pancreatic cancer	1.93e-05	0.00149	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—CNR2—pancreatic cancer	1.88e-05	0.00145	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—GLP1R—pancreatic cancer	1.88e-05	0.00145	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—CNR2—pancreatic cancer	1.88e-05	0.00145	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—GLP1R—pancreatic cancer	1.88e-05	0.00145	CbGpPWpGaD
Doxylamine—CHRM1—Circadian rythm related genes—PTEN—pancreatic cancer	1.87e-05	0.00144	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—CCKAR—pancreatic cancer	1.85e-05	0.00143	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—CCKAR—pancreatic cancer	1.85e-05	0.00143	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—IAPP—pancreatic cancer	1.84e-05	0.00142	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—IAPP—pancreatic cancer	1.83e-05	0.00141	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—ZNRF3—pancreatic cancer	1.82e-05	0.00141	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—ACVR1B—pancreatic cancer	1.82e-05	0.00141	CbGpPWpGaD
Doxylamine—CHRM1—Regulation of Actin Cytoskeleton—KRAS—pancreatic cancer	1.82e-05	0.0014	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—ACVR1B—pancreatic cancer	1.82e-05	0.0014	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—ZNRF3—pancreatic cancer	1.82e-05	0.0014	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—PTHLH—pancreatic cancer	1.76e-05	0.00136	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—PTHLH—pancreatic cancer	1.76e-05	0.00136	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—SHH—pancreatic cancer	1.69e-05	0.0013	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—SHH—pancreatic cancer	1.68e-05	0.0013	CbGpPWpGaD
Doxylamine—CHRM1—Regulation of Actin Cytoskeleton—PIK3CA—pancreatic cancer	1.67e-05	0.00129	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—IAPP—pancreatic cancer	1.67e-05	0.00129	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—IAPP—pancreatic cancer	1.66e-05	0.00128	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—DTX1—pancreatic cancer	1.65e-05	0.00127	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—SSTR3—pancreatic cancer	1.65e-05	0.00127	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—SSTR3—pancreatic cancer	1.64e-05	0.00127	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—DTX1—pancreatic cancer	1.64e-05	0.00127	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—SST—pancreatic cancer	1.61e-05	0.00124	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—SST—pancreatic cancer	1.61e-05	0.00124	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—PTHLH—pancreatic cancer	1.6e-05	0.00124	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—PTCH1—pancreatic cancer	1.6e-05	0.00124	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—PTCH1—pancreatic cancer	1.6e-05	0.00123	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—PTHLH—pancreatic cancer	1.6e-05	0.00123	CbGpPWpGaD
Doxylamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—pancreatic cancer	1.58e-05	0.00122	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—SSTR1—pancreatic cancer	1.58e-05	0.00122	CbGpPWpGaD
Doxylamine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—pancreatic cancer	1.58e-05	0.00122	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—SSTR1—pancreatic cancer	1.57e-05	0.00121	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PPY—pancreatic cancer	1.55e-05	0.00119	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PPY—pancreatic cancer	1.54e-05	0.00119	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—SSTR2—pancreatic cancer	1.52e-05	0.00117	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—SSTR2—pancreatic cancer	1.52e-05	0.00117	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—CNR1—pancreatic cancer	1.49e-05	0.00115	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—CNR1—pancreatic cancer	1.48e-05	0.00114	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CCKBR—pancreatic cancer	1.47e-05	0.00113	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—SST—pancreatic cancer	1.47e-05	0.00113	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CCKBR—pancreatic cancer	1.46e-05	0.00113	CbGpPWpGaD
Doxylamine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL8—pancreatic cancer	1.46e-05	0.00113	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—SST—pancreatic cancer	1.46e-05	0.00113	CbGpPWpGaD
Doxylamine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—pancreatic cancer	1.46e-05	0.00112	CbGpPWpGaD
Doxylamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—pancreatic cancer	1.44e-05	0.00111	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—GCG—pancreatic cancer	1.44e-05	0.00111	CbGpPWpGaD
Doxylamine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—pancreatic cancer	1.44e-05	0.00111	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—GCG—pancreatic cancer	1.43e-05	0.00111	CbGpPWpGaD
Doxylamine—HRH1—G alpha (q) signalling events—PIK3CA—pancreatic cancer	1.4e-05	0.00108	CbGpPWpGaD
Doxylamine—CHRM1—G alpha (q) signalling events—PIK3CA—pancreatic cancer	1.39e-05	0.00108	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—GLI1—pancreatic cancer	1.38e-05	0.00107	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—DTX4—pancreatic cancer	1.38e-05	0.00107	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—DTX4—pancreatic cancer	1.38e-05	0.00106	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—GLI1—pancreatic cancer	1.38e-05	0.00106	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—AGTR1—pancreatic cancer	1.37e-05	0.00106	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—AGTR1—pancreatic cancer	1.37e-05	0.00105	CbGpPWpGaD
Doxylamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—pancreatic cancer	1.36e-05	0.00105	CbGpPWpGaD
Doxylamine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—pancreatic cancer	1.36e-05	0.00105	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—CNR1—pancreatic cancer	1.35e-05	0.00104	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—CNR1—pancreatic cancer	1.35e-05	0.00104	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—NRP1—pancreatic cancer	1.34e-05	0.00104	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PPP2R5B—pancreatic cancer	1.34e-05	0.00104	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—NRP1—pancreatic cancer	1.34e-05	0.00103	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PPP2R5B—pancreatic cancer	1.34e-05	0.00103	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—GCG—pancreatic cancer	1.31e-05	0.00101	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—GCG—pancreatic cancer	1.3e-05	0.001	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—HEY2—pancreatic cancer	1.29e-05	0.000997	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—HEY2—pancreatic cancer	1.29e-05	0.000994	CbGpPWpGaD
Doxylamine—CHRM1—Circadian rythm related genes—TP53—pancreatic cancer	1.27e-05	0.000982	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—GAST—pancreatic cancer	1.26e-05	0.000974	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—GAST—pancreatic cancer	1.26e-05	0.000971	CbGpPWpGaD
Doxylamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—pancreatic cancer	1.25e-05	0.000965	CbGpPWpGaD
Doxylamine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—pancreatic cancer	1.25e-05	0.000962	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—AGTR1—pancreatic cancer	1.25e-05	0.000961	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—AGTR1—pancreatic cancer	1.24e-05	0.000958	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—SCT—pancreatic cancer	1.2e-05	0.000923	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—HEY1—pancreatic cancer	1.2e-05	0.000923	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—SCT—pancreatic cancer	1.19e-05	0.000921	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—HEY1—pancreatic cancer	1.19e-05	0.000921	CbGpPWpGaD
Doxylamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—pancreatic cancer	1.16e-05	0.000893	CbGpPWpGaD
Doxylamine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—pancreatic cancer	1.15e-05	0.00089	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CCK—pancreatic cancer	1.14e-05	0.000881	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CCK—pancreatic cancer	1.14e-05	0.000878	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—GLP1R—pancreatic cancer	1.11e-05	0.000859	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CNR2—pancreatic cancer	1.11e-05	0.000859	CbGpPWpGaD
Doxylamine—HRH1—GPCR ligand binding—CXCL8—pancreatic cancer	1.11e-05	0.000858	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CNR2—pancreatic cancer	1.11e-05	0.000856	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—GLP1R—pancreatic cancer	1.11e-05	0.000856	CbGpPWpGaD
Doxylamine—CHRM1—GPCR ligand binding—CXCL8—pancreatic cancer	1.11e-05	0.000855	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CCKAR—pancreatic cancer	1.1e-05	0.000845	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CCKAR—pancreatic cancer	1.09e-05	0.000842	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—JAG2—pancreatic cancer	1.06e-05	0.000819	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—JAG2—pancreatic cancer	1.06e-05	0.000816	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—MEN1—pancreatic cancer	1.05e-05	0.000807	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—MEN1—pancreatic cancer	1.04e-05	0.000805	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—SHH—pancreatic cancer	9.98e-06	0.00077	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—SHH—pancreatic cancer	9.95e-06	0.000768	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—NOTCH4—pancreatic cancer	9.92e-06	0.000765	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—NOTCH4—pancreatic cancer	9.89e-06	0.000763	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—IAPP—pancreatic cancer	9.86e-06	0.00076	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—IAPP—pancreatic cancer	9.83e-06	0.000758	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PTHLH—pancreatic cancer	9.46e-06	0.00073	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PTCH1—pancreatic cancer	9.46e-06	0.00073	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PTHLH—pancreatic cancer	9.43e-06	0.000728	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PTCH1—pancreatic cancer	9.43e-06	0.000728	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—SST—pancreatic cancer	8.66e-06	0.000668	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—SST—pancreatic cancer	8.63e-06	0.000666	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—PIK3CG—pancreatic cancer	8.54e-06	0.000658	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—PIK3CG—pancreatic cancer	8.51e-06	0.000656	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—JAG1—pancreatic cancer	8.47e-06	0.000653	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—JAG1—pancreatic cancer	8.44e-06	0.000651	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—NOTCH3—pancreatic cancer	8.44e-06	0.000651	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—NOTCH3—pancreatic cancer	8.41e-06	0.000649	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CNR1—pancreatic cancer	7.99e-06	0.000616	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CNR1—pancreatic cancer	7.96e-06	0.000614	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—PIK3CG—pancreatic cancer	7.75e-06	0.000598	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—PIK3CG—pancreatic cancer	7.73e-06	0.000596	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—GCG—pancreatic cancer	7.72e-06	0.000595	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—GCG—pancreatic cancer	7.69e-06	0.000593	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—PIK3CD—pancreatic cancer	7.51e-06	0.000579	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—PIK3CD—pancreatic cancer	7.48e-06	0.000577	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—AGTR1—pancreatic cancer	7.36e-06	0.000568	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—AGTR1—pancreatic cancer	7.34e-06	0.000566	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—STK11—pancreatic cancer	7.25e-06	0.000559	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—STK11—pancreatic cancer	7.23e-06	0.000558	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—PIK3CD—pancreatic cancer	6.82e-06	0.000526	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—PIK3CD—pancreatic cancer	6.79e-06	0.000524	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—PIK3CB—pancreatic cancer	6.54e-06	0.000505	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—PIK3CB—pancreatic cancer	6.52e-06	0.000503	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—SMAD4—pancreatic cancer	6.35e-06	0.00049	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—SMAD4—pancreatic cancer	6.33e-06	0.000488	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—CXCL8—pancreatic cancer	6.29e-06	0.000485	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—CXCL8—pancreatic cancer	6.27e-06	0.000483	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—HES1—pancreatic cancer	6.2e-06	0.000478	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—HES1—pancreatic cancer	6.18e-06	0.000477	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—PIK3CB—pancreatic cancer	5.94e-06	0.000458	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—PIK3CB—pancreatic cancer	5.92e-06	0.000457	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—CXCL8—pancreatic cancer	5.71e-06	0.00044	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—CXCL8—pancreatic cancer	5.69e-06	0.000439	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—TERT—pancreatic cancer	5.44e-06	0.000419	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—TERT—pancreatic cancer	5.42e-06	0.000418	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—HIF1A—pancreatic cancer	5.2e-06	0.000401	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—TSC2—pancreatic cancer	5.19e-06	0.0004	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—HIF1A—pancreatic cancer	5.18e-06	0.0004	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—TSC2—pancreatic cancer	5.17e-06	0.000399	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—APOE—pancreatic cancer	5.07e-06	0.000391	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—APOE—pancreatic cancer	5.06e-06	0.00039	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—KDR—pancreatic cancer	4.97e-06	0.000383	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—KDR—pancreatic cancer	4.96e-06	0.000382	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—NFKBIA—pancreatic cancer	4.73e-06	0.000365	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—NFKBIA—pancreatic cancer	4.71e-06	0.000364	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—NOTCH1—pancreatic cancer	4.68e-06	0.000361	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—NOTCH1—pancreatic cancer	4.67e-06	0.00036	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PIK3CG—pancreatic cancer	4.58e-06	0.000353	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—NRAS—pancreatic cancer	4.58e-06	0.000353	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PIK3CG—pancreatic cancer	4.57e-06	0.000352	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—NRAS—pancreatic cancer	4.57e-06	0.000352	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—EGF—pancreatic cancer	4.53e-06	0.000349	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—EGF—pancreatic cancer	4.51e-06	0.000348	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—EGFR—pancreatic cancer	4.17e-06	0.000322	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—EGFR—pancreatic cancer	4.16e-06	0.000321	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PIK3CD—pancreatic cancer	4.03e-06	0.000311	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PIK3CD—pancreatic cancer	4.01e-06	0.00031	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—PIK3CA—pancreatic cancer	3.99e-06	0.000308	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—PIK3CA—pancreatic cancer	3.98e-06	0.000307	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—KRAS—pancreatic cancer	3.94e-06	0.000304	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—KRAS—pancreatic cancer	3.93e-06	0.000303	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—PIK3CA—pancreatic cancer	3.62e-06	0.000279	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—PIK3CA—pancreatic cancer	3.61e-06	0.000278	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PIK3CB—pancreatic cancer	3.51e-06	0.000271	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PIK3CB—pancreatic cancer	3.5e-06	0.00027	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CXCL8—pancreatic cancer	3.37e-06	0.00026	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CXCL8—pancreatic cancer	3.36e-06	0.000259	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—HRAS—pancreatic cancer	3.35e-06	0.000258	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—HRAS—pancreatic cancer	3.34e-06	0.000258	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—AKT1—pancreatic cancer	3.26e-06	0.000251	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—AKT1—pancreatic cancer	3.25e-06	0.00025	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CASP3—pancreatic cancer	3.23e-06	0.000249	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CASP3—pancreatic cancer	3.22e-06	0.000248	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CCND1—pancreatic cancer	3.14e-06	0.000242	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CCND1—pancreatic cancer	3.13e-06	0.000242	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—CTNNB1—pancreatic cancer	3.11e-06	0.00024	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—CTNNB1—pancreatic cancer	3.1e-06	0.000239	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—MMP9—pancreatic cancer	3.05e-06	0.000235	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—MMP9—pancreatic cancer	3.04e-06	0.000235	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PTEN—pancreatic cancer	3.03e-06	0.000234	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PTEN—pancreatic cancer	3.02e-06	0.000233	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—AKT1—pancreatic cancer	2.96e-06	0.000228	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—AKT1—pancreatic cancer	2.95e-06	0.000227	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—SRC—pancreatic cancer	2.81e-06	0.000217	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—SRC—pancreatic cancer	2.8e-06	0.000216	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—VEGFA—pancreatic cancer	2.74e-06	0.000211	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—VEGFA—pancreatic cancer	2.73e-06	0.000211	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—STAT3—pancreatic cancer	2.71e-06	0.000209	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—NRAS—pancreatic cancer	2.71e-06	0.000209	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—STAT3—pancreatic cancer	2.7e-06	0.000209	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—NRAS—pancreatic cancer	2.7e-06	0.000208	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—MYC—pancreatic cancer	2.52e-06	0.000194	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—TGFB1—pancreatic cancer	2.51e-06	0.000194	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—MYC—pancreatic cancer	2.51e-06	0.000194	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—TGFB1—pancreatic cancer	2.51e-06	0.000193	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—EGFR—pancreatic cancer	2.46e-06	0.00019	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—EGFR—pancreatic cancer	2.46e-06	0.00019	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—KRAS—pancreatic cancer	2.33e-06	0.00018	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—KRAS—pancreatic cancer	2.32e-06	0.000179	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—PIK3CA—pancreatic cancer	2.14e-06	0.000165	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—PIK3CA—pancreatic cancer	2.13e-06	0.000164	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—TP53—pancreatic cancer	2.07e-06	0.00016	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—TP53—pancreatic cancer	2.06e-06	0.000159	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—HRAS—pancreatic cancer	1.98e-06	0.000153	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—HRAS—pancreatic cancer	1.97e-06	0.000152	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—AKT1—pancreatic cancer	1.75e-06	0.000135	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—AKT1—pancreatic cancer	1.74e-06	0.000134	CbGpPWpGaD
